Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will participate in the 2024 RBC Capital Markets Global Healthcare Conference with a fireside chat on May 15.

Rhea-AI Summary

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will participate in the 2024 RBC Capital Markets Global Healthcare Conference with a fireside chat on May 15. The live webcast can be accessed on the company's website.

Argus Session date unavailable

+4.90% session move Open Argus

Details

News Market Reaction – KPTI

The recorded move for KPTI in the trading session of this news was +4.90%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWTON, Mass., May 8, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 2024 RBC Capital Markets Global Healthcare Conference in a fireside chat on Wednesday, May 15 at 9:30 a.m. ET.

A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay following the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-the-2024-rbc-capital-markets-global-healthcare-conference-302138529.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Karyopharm participate in the 2024 RBC Capital Markets Global Healthcare Conference?

Karyopharm will participate in the conference on May 15.

What time will the fireside chat take place on May 15?

The fireside chat will be at 9:30 a.m. ET.

Where can the live webcast of the fireside chat be accessed?

The webcast can be accessed on the company's website under 'Events & Presentations'.

Will the webcast be available for replay?

Yes, the webcast will be available for replay following the event.